179 related articles for article (PubMed ID: 28481707)
21. Which Patients With Cervical Squamous Cell Carcinoma Might Benefit From Neoadjuvant Chemotherapy?
Mahmoud O; Einstein MH
J Clin Oncol; 2018 Jun; 36(16):1543-1547. PubMed ID: 29668367
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy for bladder cancer.
Sonpavde G; Lerner SP
Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
[TBL] [Abstract][Full Text] [Related]
23. Complete response of bony metastatic bladder urothelial cancer to neoadjuvant chemotherapy and cystectomy.
Joudi FN; Dahmoush L; Spector DM; Konety BR
Urol Oncol; 2006; 24(5):403-6. PubMed ID: 16962489
[TBL] [Abstract][Full Text] [Related]
24. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study.
Leveridge MJ; Siemens DR; Mackillop WJ; Peng Y; Tannock IF; Berman DM; Booth CM
Urology; 2015 Apr; 85(4):791-8. PubMed ID: 25661830
[TBL] [Abstract][Full Text] [Related]
25. Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors.
Pagliaro LC
J Clin Oncol; 2017 Apr; 35(10):1036-1040. PubMed ID: 27992270
[TBL] [Abstract][Full Text] [Related]
26. Defining optimal therapy for muscle invasive bladder cancer.
Herr HW; Dotan Z; Donat SM; Bajorin DF
J Urol; 2007 Feb; 177(2):437-43. PubMed ID: 17222605
[TBL] [Abstract][Full Text] [Related]
27. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder.
Dimopoulos MA; Moulopoulos LA
J Clin Oncol; 1998 Apr; 16(4):1601-12. PubMed ID: 9552072
[TBL] [Abstract][Full Text] [Related]
28. Optimization of Risk Stratification in Localized Prostate Cancer.
Morgans AK
J Clin Oncol; 2018 Feb; 36(6):528-532. PubMed ID: 29303624
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy versus cystectomy in management of stages II, and III urinary bladder cancer.
Osman MA; Gabr AM; Elkady MS
Arch Ital Urol Androl; 2014 Dec; 86(4):278-83. PubMed ID: 25641451
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of risk of muscle invasion, perivesical and/or lymph node affectation by diffusion-weighted magnetic nuclear resonance in the patient who is a candidate for radical cystectomy.
Lista F; Andrés G; Cáceres F; Ramón de Fata F; Rodríguez-Barbero JM; Angulo JC
Actas Urol Esp; 2013; 37(7):419-24. PubMed ID: 23773823
[TBL] [Abstract][Full Text] [Related]
31. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
32. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients.
Picozzi S; Ricci C; Gaeta M; Ratti D; Macchi A; Casellato S; Bozzini G; Carmignani L
J Urol; 2012 Dec; 188(6):2046-54. PubMed ID: 23083867
[TBL] [Abstract][Full Text] [Related]
33. Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?
Bouberhan S; Shea M; Cannistra SA
J Clin Oncol; 2019 Jun; 37(16):1359-1364. PubMed ID: 31002579
[No Abstract] [Full Text] [Related]
34. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
Zargar-Shoshtari K; Zargar H; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
J Urol; 2016 Jan; 195(1):53-9. PubMed ID: 26205531
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy in patients with invasive bladder cancer.
Vaughn DJ; Malkowicz SB
Urol Clin North Am; 2005 May; 32(2):231-7. PubMed ID: 15862620
[TBL] [Abstract][Full Text] [Related]
36. Presacral and retroperitoneal lymph node involvement in urothelial bladder cancer: results of a prospective mapping study.
Miocinovic R; Gong MC; Ghoneim IA; Fergany AF; Hansel DE; Stephenson AJ
J Urol; 2011 Oct; 186(4):1269-73. PubMed ID: 21849181
[TBL] [Abstract][Full Text] [Related]
37. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
Lavery HJ; Stensland KD; Niegisch G; Albers P; Droller MJ
J Urol; 2014 Apr; 191(4):898-906. PubMed ID: 24300483
[TBL] [Abstract][Full Text] [Related]
38. Management of Stage II Germ Cell Tumors: Be Sure, Be Patient, Be Safe.
Kollmannsberger CK; Nappi L; Nichols C
J Clin Oncol; 2019 Aug; 37(22):1856-1862. PubMed ID: 31180818
[No Abstract] [Full Text] [Related]
39. Laparoendoscopic single-site radical cystectomy and pelvic lymph node dissection: initial experience and 2-year follow-up.
Kaouk JH; Goel RK; White MA; White WM; Autorino R; Haber GP; Campbell SC
Urology; 2010 Oct; 76(4):857-61. PubMed ID: 20646750
[TBL] [Abstract][Full Text] [Related]
40. To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer.
Higano CS
J Clin Oncol; 2014 Apr; 32(11):1107-11. PubMed ID: 24590651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
